À titre de membre permanent, vous pourrez accéder au contenu éditorial et de formation continue, utiliser le moteur de recherche, recevoir nos newsletters, participer aux discussions, télécharger des diapositives et plus encore.
Prostanoids are the most potent therapies for PAH, yet they are underused. Drs. Waxman, Frantz, and Chakinala discuss barriers to their use and when and how to use them.
PARTNER, RIFLE, TWENTE, transcatheter valves, novel DES, and renal denervation — Drs. Worthley and Meredith give their take on the hot topics for the interventionalist.
Evidence shows that hypertension remains poorly controlled throughout the world. Join us, as you are invited to participate in this educational survey to gauge physician practice patterns in the management of hypertension.
Despite monotherapy, a 38-year-old woman with PAH still has significant functional limitations. Dr McLaughlin reviews the treatment options for this patient.
Hypertension affects approximately 73 million adults in the U.S. and is one of the most important risk factors for cardiovascular and renal diseases. Dr. Kountz will focus on current hypertension treatment disparities and high-risk patients while providing a thorough exploration of guideline-based management strategies.
Hypertension, hypercholesterolemia, insulin resistance, atherosclerosis, coronary heart disease, heart failure: are they all at the mercy of nitric oxide? Join Drs Weber, Cohn, Mason and Cockcroft in a discussion on the role nitric oxide plays in vascular health.
Prostanoids are the most potent therapies for PAH, yet they are underused. Drs. Waxman, Frantz, and Chakinala discuss barriers to their use and when and how to use them.